GlassScriptPhysician profile
Sunita Banerjee
NPI 1710993787
$1,553.50
in general payments reported to CMS, 2019-2025
30 companies · $615 in 2025
The $615 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $394 · 2020: $139 · 2022: $129 · 2023: $276 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $891.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $155.96 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $147.62 | 2019-2025 | Airsupra, Farxiga, Fasenra |
| Novartis Pharmaceuticals Corporation | $126.55 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.90 | 2019-2025 | |
| Novo Nordisk INC | $115.58 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.72 | 2020-2025 | Xifaxan |
| Dexcom, INC. | $96.26 | 2023-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $68.16 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $62.72 | 2019-2020 | |
| Abbvie INC. | $60.35 | 2025 | |
| Lilly USA, LLC | $49.64 | 2019-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $48.20 | 2019-2023 | Spravato |
| Amgen INC. | $44.34 | 2022-2023 | Otezla, Repatha |
| Becton, Dickinson and Company | $34.27 | 2019 | |
| Lundbeck LLC | $33.85 | 2025 | Rexulti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $29.68 | 2019 | |
| Sanofi-Aventis U.S. LLC | $28.24 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $26.85 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $24.11 | 2022 | |
| Radius Health, INC. | $22.11 | 2025 | Tymlos |
| Daiichi Sankyo INC. | $19.73 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.80 | 2022 | |
| Fresenius Kabi USA, LLC | $17.49 | 2023 | |
| Glaxosmithkline, LLC. | $14.76 | 2022 | |
| Phadia US INC. | $14.70 | 2023 | Immunocap |
| Mylan Specialty L.P. | $14.67 | 2019 | |
| Amarin Pharma, INC. | $14.53 | 2019 | |
| Celgene Corporation | $12.73 | 2023 | Zeposia |
| Allergan, INC. | $12.09 | 2019 | |
| Endogastric Solutions, INC | $9.89 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunita Banerjee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.